Overview

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

The current study is designed to confirm the mechanism behind the increase in serum creatinine observed during GSK1349572 therapy; specifically, the study will determine whether GSK1349572 has any effect on glomerular filtration rate (GFR) or effective renal plasma flow. Absent such effects, one may conclude that the small increases in serum creatinine observed are due to the inhibition of the tubular secretion of creatinine via organic cation transporter 2 (OCT2) consistent with in vitro data. .

Phase:

Phase 1

Details

Lead Sponsor:

ViiV Healthcare

Collaborators:

GlaxoSmithKline
Shionogi

Treatments:

Dolutegravir